BioXcel Therapeutics
BTAI
117 hedge funds and large institutions have $567M invested in BioXcel Therapeutics in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 30 reducing their positions, and 17 closing their positions.
143% more call options, than puts
Call options by funds: $28.8M | Put options by funds: $11.9M
57% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 30
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
11% more capital invested
Capital invested by funds: $512M → $567M (+$55M)
8% more funds holding
Funds holding: 108 → 117 (+9)
0.17% less ownership
Funds ownership: 3.32% → 3.15% (-0.17%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.5M |
| 2 |
Goldman Sachs
New York
|
+$4.72M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.63M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$4.59M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$11.7M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$8.61M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.84M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.79M |
| 5 |
Jane Street
New York
|
-$2.19M |
BTAI Hedge Fund Activity: Q4 2020 in Review
117 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2020, worth a combined $567M — up 11% from $512M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BTAI positions and 17 closed out — a net gain of 9 holders — while 47 added to existing stakes and 30 trimmed.
The largest buyer was State Street, adding an estimated $18.5M. The largest seller was Sphera Funds Management, cutting an estimated $11.7M.
- 117 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2020, up from 108 in Q3 2020.
- Funds reported $567M of BioXcel Therapeutics stock for Q4 2020, up 11% quarter-over-quarter.
- 26 funds opened new BioXcel Therapeutics positions in Q4 2020 and 17 closed out, a net change of +9 holders.
- The largest BioXcel Therapeutics buyer in Q4 2020 was State Street, an estimated $18.5M added.
- The largest BioXcel Therapeutics seller in Q4 2020 was Sphera Funds Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2020.